Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.35 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22899135 | 0.87 | TNF (0.37) | GBA1LGALS8CD209GAA | |
| SCHEMBL19656077 | 0.84 | GBA1 (0.38) | GBA1LGALS8CD209G6PDGAA | |
| SCHEMBL14772011 | 0.82 | GBA1 (0.35) | GBA1CD209 | |
| SCHEMBL13944218 | 0.80 | GAA (0.46) | GBA1CD209G6PDGAA | |
| SCHEMBL21738582 | 0.80 | GAA (0.46) | GBA1CD209G6PDGAA | |
| SCHEMBL23689997 | 0.80 | GAA (0.46) | GBA1CD209G6PDGAA | |
| SCHEMBL13908121 | 0.80 | GAA (0.46) | GBA1CD209G6PDGAA | |
| SCHEMBL17342338 | 0.80 | GAA (0.46) | GBA1CD209G6PDGAA | |
| SCHEMBL15314716 | 0.80 | GAA (0.46) | GBA1CD209G6PDGAA | |
| SCHEMBL19720228 | 0.80 | GAA (0.46) | GBA1CD209G6PDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | GBA1 1553/4885LGALS8 593/4885CD209 233/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | GBA1 1264/4885LGALS8 769/4885CD209 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.